COVID-19 Vaccine Authorized in India-A Mini Review

preprint OA: gold publisher-OA-unknown
🔓 Open OA copy View at publisher

Abstract

Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which is responsible for Coronavirus disease (COVID-19) has spread to 220 countries and has been found to be challenging. Many variants detected after Wuhan-Hu-1 reference which were able to develop the resistance against the neutralizing antibodies induced by vaccine and may cause false negative results in diagnostic tests targeting the S gene. The COVID-19 cases are increasing rapidly in India and the government authorized a new vaccine for restricted use in emergency situation. This review discusses about the efficacy, safety, and economical aspects of vaccines authorized in India. The rAd26-s & rAd5-s (Gamaleya Research Institute of Epidemiology and Microbiology) demonstrate high efficacy as well as safety, followed by BBV152 (Bharat Biotech) and AZD1222 (Oxford AstraZeneca); AZD1222 is more economical than other two.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-05-19T01:45:01.086888+00:00
unpaywall
last seen: 2026-05-21T02:00:01.467718+00:00
License: publisher-OA-unknown · commercial use NOT OK · attribution required